89bio, Inc. (ETNB) analyst actions
Rating and price-target actions on ETNB in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ETNB overview →
3 measured ETNB analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis | Press release | +2.35% | +2.48% | |
| 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis | Press release | -0.27% | -0.08% | |
| 89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 | Press release | +0.90% | +1.34% |
Keep exploring
More ETNB: earnings → · SEC filings → · ETNB overview →